Articles tagged with Ankylosing Spondylitis
Elevated Pim1 expression promotes abnormal Th17 cell differentiation in inflammatory arthritis. Targeting Pim1 with Nilotinib inhibits Th17 cell differentiation and alleviates inflammatory arthritis symptoms.
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
A study found that people with a specific genetic mutation in the CARD9 gene have higher IL-17 protein levels, making them more responsive to IL-17 inhibitor biologics. This discovery may lead to targeted treatment recommendations for ankylosing spondylitis patients.
A Swansea University study reveals the potential of machine learning in identifying Ankylosing Spondylitis (AS) patients, reducing diagnosis delays from eight years to earlier. The research uses a national data repository to develop a predictive model for AS detection, empowering GPs to refer patients more efficiently.
Researchers develop new method to identify crucial protein fragments driving autoimmunity, enabling better diagnostics and therapies. The study finds cross-reactivity between human and microbial proteins drives autoimmunity in at least two diseases.
A study of infants and young children with mothers having ankylosing spondylitis (AS) found their growth and development comparable to offspring of other women. Despite having a rheumatic disease, mothers can have healthy children.
A cohort study showed that adding non-steroidal anti-inflammatory drugs (NSAIDs) to tumour necrosis factor (TNF) inhibitors can slow radiographic progression in patients with ankylosing spondylitis. Celecoxib, a specific NSAID, was associated with the greatest reduction in radiographic progression.
A population study shows that individuals with AS are almost twice as likely to self-harm compared to their comparators. The most frequent method of self-harm is poisoning or self-mutilation. This study highlights the need for routine evaluation of self-harm behavior in patients with chronic inflammatory arthritis.
Patients who experience negative symptoms during biosimilar treatment attribute them incorrectly to the new medication. Effective communication between clinicians and patients is crucial for successful transitioning.
Researchers found a significant interaction between TNF-inhibitors and NSAIDs, with patients experiencing a 70% reduction in radiographic progression when used together. The study suggests that combining these therapies may be especially helpful for patients at higher risk of disease progression.
Researchers at the University of Southampton have identified a genetic variation in the ERAP1 enzyme that increases an individual's susceptibility to Ankylosing Spondylitis. Genetic testing for this variation may enable earlier diagnosis and improved management of the condition.
Researchers used CT scans to investigate royal Egyptian mummies from the 18th-20th Dynasties, ruling out signs of ankylosing spondylitis. Instead, they found evidence of diffuse idiopathic skeletal hyperostosis (DISH) in four Pharaohs, suggesting a degenerative spinal condition, not inflammatory arthritis.
New data show that biosimilar CT-P13 achieves statistically similar improvements in disease activity, disability, and mobility in patients with Ankylosing Spondylitis compared to its original reference product infliximab. The results demonstrate comparable efficacy and safety for CT-P13 as an alternative treatment option.
Researchers discovered seven new genes linked to Ankylosing Spondylitis, bringing the total to thirteen known predisposing genes. The study also revealed an interaction between genetic mutations HLA-B27 and ERAP1, providing insight into the disease's cause.
A study involving over 5,000 people with ankylosing spondylitis has identified three regions of the genome strongly associated with the condition. The findings suggest that a particular process in cells and genetic variants of ERAP1 interact to affect disease susceptibility.
Researchers at UT Health Science Center at Houston identify two new genes implicated in ankylosing spondylitis and pinpoint areas regulating gene activity associated with the condition. The study brings the scientific community closer to understanding AS, a chronic form of arthritis affecting millions worldwide.
A long-term study of 1,471 patients with ankylosing spondylitis who received repeated intravenous injections of 224Radium found a significantly increased rate of leukaemias, particularly acute myeloid leukaemia, compared to a control group
Patients with painful and progressive ankylosing spondylitis showed significant improvements in physical function and symptoms after golimumab treatment, with 51-66% achieving ASAS 20 or 40 at six months.
Researchers have identified two genes, ARTS1 and IL23R, that increase the risk of developing ankylosing spondylitis, a common disease causing back pain and progressive stiffness. A potential treatment for Crohn's disease may also be applied to this disease, providing a major step towards being able to treat ankylosing spondylitis.
An international team of researchers has discovered two genes linked to ankylosing spondylitis, a painful and progressive disease affecting the spine. The study also validated the association of two genes implicated in Graves' disease, increasing the number of known genes involved in both diseases.
Patients with ankylosing spondylitis who received REMICADE showed significant improvement in spinal mobility and reduced spinal inflammation over two years. This study found that REMICADE-treated patients experienced sustained reductions in spinal inflammation, as detected by magnetic resonance imaging (MRI), compared to placebo group.
Patients with ankylosing spondylitis who received Enbrel treatment experienced sustained improvements in signs and symptoms, spinal mobility, and physical function over 148-160 weeks. A total of 78% of patients achieved a 20% improvement in the Assessment on Ankylosing Spondylitis Response Criteria (ASAS) after 160 weeks.
A Phase 3 study showed ENBREL significantly improved back pain, mobility, and function in patients with ankylosing spondylitis. At 12 weeks, 60% of patients achieved a 20% improvement, while at 24 weeks, 58% did so.
A recent survey found that people with ankylosing spondylitis often experience delayed diagnosis, with two-thirds not receiving a proper diagnosis until at least five years after symptoms began. This delay can lead to permanent spinal damage and disability, affecting daily life, including mobility, sleep, and sex life.
A UCSF study shows that 80% of patients taking etanercept experience significant relief from ankylosing spondylitis symptoms. The drug reduces spinal inflammation and slows disease progression, offering a new therapeutic option for the chronic inflammatory arthritis.
A Phase 2 double-blind, placebo-controlled study found that 40 patients with ankylosing spondylitis achieved a significant clinical response when treated with ENBREL (etanercept), with 80% of patients showing improvement in outcome measures. The treatment was generally well-tolerated with no serious adverse events or withdrawals.